Kavirajan, H; Schneider, LS (September 2007). “Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.”. 《The Lancet. Neurology》 6 (9): 782–92. doi:10.1016/s1474-4422(07)70195-3. PMID17689146.
GBD 2015 Mortality and Causes of Death, Collaborators. (2016년 10월 8일). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.”. 《Lancet》 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMID27733281.
Birks, J (2006년 1월 25일). “Cholinesterase inhibitors for Alzheimer's disease.”. 《The Cochrane database of systematic reviews》 (1): CD005593. doi:10.1002/14651858.CD005593. PMID16437532.
Rolinski, M; Fox, C; Maidment, I; McShane, R (2012년 3월 14일). “Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.”. 《The Cochrane database of systematic reviews》 3: CD006504. doi:10.1002/14651858.CD006504.pub2. PMID22419314.
Forbes, Dorothy; Forbes, Scott C.; Blake, Catherine M.; Thiessen, Emily J.; Forbes, Sean (2015년 4월 15일). “Exercise programs for people with dementia”. 《The Cochrane Database of Systematic Reviews》 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. ISSN1469-493X. PMID25874613.
Lin, J.S.; O'Connor, E.; Rossom, R.C.; Perdue, L.A.; Eckstrom, E. (2013년 10월 22일). “Screening for Cognitive Impairment in Older Adults: A Systematic Review for the U.S. Preventive Services Task Force.”. 《Annals of Internal Medicine》 159 (9): 601–12. doi:10.7326/0003-4819-159-9-201311050-00730. PMID24145578.
Kavirajan, H; Schneider, LS (September 2007). “Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.”. 《The Lancet. Neurology》 6 (9): 782–92. doi:10.1016/s1474-4422(07)70195-3. PMID17689146.
Commission de la transparence (June 2012). “Médicaments de la maladie d'Alzheimer: à éviter” [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage]. 《Prescrire Int》 21 (128): 150. PMID22822592.
GBD 2015 Mortality and Causes of Death, Collaborators. (2016년 10월 8일). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.”. 《Lancet》 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMID27733281.
Birks, J (2006년 1월 25일). “Cholinesterase inhibitors for Alzheimer's disease.”. 《The Cochrane database of systematic reviews》 (1): CD005593. doi:10.1002/14651858.CD005593. PMID16437532.
Rolinski, M; Fox, C; Maidment, I; McShane, R (2012년 3월 14일). “Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.”. 《The Cochrane database of systematic reviews》 3: CD006504. doi:10.1002/14651858.CD006504.pub2. PMID22419314.
Forbes, Dorothy; Forbes, Scott C.; Blake, Catherine M.; Thiessen, Emily J.; Forbes, Sean (2015년 4월 15일). “Exercise programs for people with dementia”. 《The Cochrane Database of Systematic Reviews》 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. ISSN1469-493X. PMID25874613.
Lin, J.S.; O'Connor, E.; Rossom, R.C.; Perdue, L.A.; Eckstrom, E. (2013년 10월 22일). “Screening for Cognitive Impairment in Older Adults: A Systematic Review for the U.S. Preventive Services Task Force.”. 《Annals of Internal Medicine》 159 (9): 601–12. doi:10.7326/0003-4819-159-9-201311050-00730. PMID24145578.
Forbes, Dorothy; Forbes, Scott C.; Blake, Catherine M.; Thiessen, Emily J.; Forbes, Sean (2015년 4월 15일). “Exercise programs for people with dementia”. 《The Cochrane Database of Systematic Reviews》 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. ISSN1469-493X. PMID25874613.
Geddes, John; Gelder, Michael G.; Mayou, Richard (2005). 《Psychiatry》. Oxford [Oxfordshire]: Oxford University Press. 141쪽. ISBN0-19-852863-9. OCLC56348037.